secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2026-05-15T20:13:11+00:00
Accession:  0001193125-26-226747
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation
-----------------------------------------------------------------------------

- Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.
- Net loss $6.9M ($1.05 per share) vs $17.4M in Q1 2025 (post reverse split).
- Revenue $1.0M from CPRIT grant and CNSide billings; operating loss $7.1M vs $3.5M year ago.
- FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and ependymoma.
- CNSide expanded payer coverage to ~81M lives including Blue Shield of California; unique PLA code secured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/0001193125-26-226747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/pstv-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-226747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer